Panalgo, a leading healthcare analytics company, today announced that its Instant Health Data (IHD) platform will be used by the European Medicines Agency (EMA) to facilitate the analysis of real-world data.
EMA will use IHD to undertake rapid analyses of Electronic Healthcare Data (EHDs) accessible in-house (currently data from the UK, France, and Germany) to more quickly examine drug utilization, assess safety/efficacy, understand how treatments perform in real-world settings, and support public health efforts in the European Union (EU).
“We are excited to partner with the EMA to support its mission of ensuring the efficacy and safety of medical products throughout the EU. Our company is strongly aligned with the EMA’s public health goals, for which timely evidence-based insights are of particular importance, especially during this COVID-19 pandemic,” said Joseph Menzin, PhD, Chief Executive Officer of Panalgo. Read more here.
(Source: Cision Newswire; 1/6/21)
